UnicoCell Biomed Co., Ltd. (6794.TW)

TWD 70.8

(0.28%)

EBITDA Summary of UnicoCell Biomed Co., Ltd.

  • UnicoCell Biomed Co., Ltd.'s latest annual EBITDA in 2023 was -56.27 Million TWD , up 14.25% from previous year.
  • UnicoCell Biomed Co., Ltd.'s latest quarterly EBITDA in 2024 Q2 was -17.65 Million TWD , up 23.98% from previous quarter.
  • UnicoCell Biomed Co., Ltd. reported an annual EBITDA of -65.62 Million TWD in 2022, down -10.4% from previous year.
  • UnicoCell Biomed Co., Ltd. reported an annual EBITDA of -59.44 Million TWD in 2021, up 29.74% from previous year.
  • UnicoCell Biomed Co., Ltd. reported a quarterly EBITDA of -23.22 Million TWD for 2024 Q1, down -5.85% from previous quarter.
  • UnicoCell Biomed Co., Ltd. reported a quarterly EBITDA of -21.94 Million TWD for 2023 Q3, down -123.4% from previous quarter.

Annual EBITDA Chart of UnicoCell Biomed Co., Ltd. (2023 - 2019)

Historical Annual EBITDA of UnicoCell Biomed Co., Ltd. (2023 - 2019)

Year EBITDA EBITDA Growth
2023 -56.27 Million TWD 14.25%
2022 -65.62 Million TWD -10.4%
2021 -59.44 Million TWD 29.74%
2020 -84.6 Million TWD 7.65%
2019 -91.6 Million TWD 0.0%

Peer EBITDA Comparison of UnicoCell Biomed Co., Ltd.

Name EBITDA EBITDA Difference
Apex Biotechnology Corp. 221.06 Million TWD 125.457%
Sinphar Pharmaceutical Co.,Ltd. 582.94 Million TWD 109.654%
Panion & Bf Biotech Inc. 327.21 Million TWD 117.198%
Chunghwa Chemical Synthesis & Biotech Co., Ltd. 473.81 Million TWD 111.877%
GenMont Biotech Incorporation 71.76 Million TWD 178.414%
Abnova (Taiwan) Corporation 81.2 Million TWD 169.298%
Adimmune Corporation -512.42 Million TWD 89.018%
Tanvex BioPharma, Inc. -1.75 Billion TWD 96.792%
Polaris Group -1.38 Billion TWD 95.95%
Energenesis Biomedical CO.,LTD. -244.57 Million TWD 76.99%
PELL Bio-Med Technology Co. Ltd. -353.17 Million TWD 84.066%